BSE - Delayed Quote INR

Mangalam Drugs & Organics Limited (MANGALAM.BO)

101.95

-9.70

(-8.69%)

At close: 3:27:27 PM GMT+5:30

Sonos, Abercrombie & Fitch, Howard Hughes: Trending Tickers

Wealth host Brad Smith shares company updates and stock reactions for the top trending tickers on Yahoo Finance. Sonos (SONO) CEO Patrick Spence is resigning following issues with the company's new mobile app that left customers unable to connect to or use their speakers. The Board has appointed Tom Conrad as interim CEO as they search for a replacement. Abercrombie & Fitch (ANF) stock is declining despite the retailer raising its fourth quarter sales growth forecast to 7 to 8%, up from previous guidance of 5 to 7%. The company also increased its full-year net sales outlook. Meanwhile, Howard Hughes (HHH) stock is climbing after it received a proposed merger offer from Bill Ackman's Pershing Square (PSHZF) valued at $85 per share. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Angel Smith

Yahoo Finance Video 11 minutes ago

HHH

ANF

PSHZF
Lululemon and Macy's give Q4 sales updates

Macy's (M) and Lululemon (LULU) are in focus after the retailers released early estimates for the fourth quarter. Lululemon raised its profit and sales target for the quarter, while Macy's indicated sales are at the low end or below its guidance. Seana Smith and Brad Smith examine what the updates signal about the retail giants and what Lululemon and Macy's investors need to know. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Naomi Buchanan.

Yahoo Finance Video 1 hour ago

M

LULU
Moderna stock plunges on sales forecast cut

Moderna (MRNA) shares tumble after the pharmaceutical company lowered its sales forecast amid weak demand for COVID and RSV vaccines. Seana Smith and Brad Smith outline what investors need to know about the sales cut. The sales outlook cut comes ahead of President-elect Donald Trump’s return to the White House, fueling uncertainty given that Trump’s Food and Drug Administration (FDA) nomination, Robert F. Kennedy Jr., has been outspoken with his antivaccine views. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Naomi Buchanan.

Yahoo Finance Video 1 hour ago

MRNA
A Mixed Bag of Factors Influencing Moderna's Stock This Month

Moderna's Stock Roller Coaster: From Highs to Lows

GuruFocus.com 6 minutes ago

MRNA
Why Moderna Stock Just Crashed 21%

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new guidance for 2025. Moderna estimates it ended 2024 with somewhere between $3 billion and $3.1 billion in product sales as it shifted its business toward treating COVID-19 as an "endemic" illness rather than a novel and spreading pandemic.

Motley Fool 7 minutes ago

MRNA
Cleveland-Cliffs partners with Nucor to potentially bid for US Steel, CNBC reports

Cleveland-Cliffs is partnering with peer Nucor to prepare a potential bid for U.S. Steel, CNBC reported on Monday, citing sources. According to the report, Cleveland-Cliffs would purchase U.S. Steel in an all-cash deal and then sell the company's Big River Steel subsidiary to Nucor. U.S. Steel's headquarters would remain in Pittsburgh under the deal, CNBC added.

Reuters 14 minutes ago

X

NUE
Illumina and NVIDIA Just Dropped a Genomics Bombshell

This partnership could disrupt healthcare, revolutionize drug discovery, and spark the next AI-powered stock surge.

GuruFocus.com 24 minutes ago

NVDA

ILMN
Moderna's Stock Crashes 22%--Pandemic Hero Now Fighting for Survival

Revenue forecasts slashed, vaccine sales dive, and Wall Street loses patience--can Moderna bounce back?

GuruFocus.com 32 minutes ago

MRNA
Why Madrigal Pharmaceuticals Stock Is Sinking Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. Madrigal reported preliminary Q4 net sales for its metabolic steatohepatitis (MASH) drug Rezdiffra of between $100 million and $103 million. Madrigal also stated that it should end 2024 with cash, cash equivalents, restricted cash, and marketable securities of around $931 million.

Motley Fool 33 minutes ago

MDGL
US extends deadline on Nippon's bid for US Steel, offering some hope that the deal is not dead

The bid by Japan's Nippon Steel to buy U.S. Steel may have a new lease on life after the Biden Administration extended a deadline for the Japanese steelmaker to abandon plans to acquire the storied Pittsburgh company after President Joe Biden blocked the deal. The new deadline, now in mid-June, was viewed by U.S. Steel — and investors — as an opportunity for the companies to complete the acquisition, even though President-elect Donald Trump, who takes office in a week, also opposes the deal. Biden nixed the acquisition this month citing a potential threat to national security, though the U.S. Committee on Foreign Investment in the United States, known as CFIUS, failed to reach a consensus on the security issue.

Associated Press Finance 35 minutes ago

X
Steel Wars: U.S. Steel Shares Soar 8% Amid $14.9B Deal Chaos

Biden blocks Nippon Steel's bid, rivals circle, and legal battles ignite investor frenzy.

GuruFocus.com 1 hour ago

X
US Steel Rises on CNBC Report of American Rivals Mulling Bid

(Bloomberg) -- United States Steel Corp. shares rose after CNBC reported that Cleveland-Cliffs Inc. and Nucor Corp. are considering a takeover bid of the iconic American steelmaker.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyA Blueprint for Better Bike LanesWhat Robotaxis Brought San FranciscoAmbitious High-Speed Rail Plans Advance in the Baltic RegionNew York, San Francisco Ranked Worst for US Traffic in City CentersCliffs would purchase all of US Steel for

Bloomberg 1 hour ago

X

NUE

CLF
Moderna Lowers Full-Year Revenue Outlook, Plans to Cut Cash Costs By $1 Billion

Moderna (MRNA) shares fell intraday Monday after the company cut its full-year revenue outlook while

PREMIUM
MT Newswires 1 hour ago

MRNA
Stock Market Today: Dow Jones Up Even As Nvidia Swoons On Biden Move; This Stock Soars On Bill Ackman Offer (Live Coverage)

The Dow Jones rose even as other indexes fell on the stock market today. Nvidia swooned on a Biden AI move. Bill Ackman made an offer.

Investor's Business Daily 1 hour ago

HHH

MRNA

AAPL
Humana, UnitedHealth, CVS Jump On Potential Medicare Advantage Payment Boost

This positive news overshadowed the negative impact of recent California wildfires on the insurance sector.

GuruFocus.com 1 hour ago

UNH

HUM

CVS
Lululemon Lifts Q4 Sales, Profit Outlook After Holiday Shopping Season

Lululemon Athletica raised its fourth-quarter sales and profit projections after its finance chief said "guests responded well" to its product offering during the holiday season.

Investopedia 1 hour ago

LULU
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday that it will pay $132 in cash for each share of Intra-Cellular. Intra-Cellular Therapies Inc. makes Caplyta, a once-daily pill for treating adults with schizophrenia and depression tied to bipolar disorder.

Associated Press Finance 1 hour ago

ITCI

JNJ
Why UNH, CVS and HUM Are Advancing Today

The shares of UnitedHealth (UNH), CVS (CVS) and Humana (HUM) are climbing about 3.2%, 4% and 6%, respectively, today after the Biden administration on Friday proposed significantly raising the amount that the government pays to insurers who offer Medicare Advantage plans. UnitedHealth, CVS and Humana provide Medicare beneficiaries with those plans. The Details of the […]

Insider Monkey 1 hour ago

UNH
Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance

Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting initiative.

Investor's Business Daily 1 hour ago

MRNA
Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition

J&J's acquisition of Intra-Cellular Therapies reshapes its portfolio with schizophrenia, bipolar, and Alzheimer's treatments.

GuruFocus.com 1 hour ago

JNJ

ITCI

Performance Overview

Return	MANGALAM.BO	S&P BSE SENSEX
YTD	-13.57%	-2.45%
1-Year	-3.12%	+5.18%
3-Year	-30.69%	+24.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mangalam Drugs & Organics Limited (MANGALAM.BO)

Related News

Sonos, Abercrombie & Fitch, Howard Hughes: Trending Tickers

Lululemon and Macy's give Q4 sales updates

Moderna stock plunges on sales forecast cut

A Mixed Bag of Factors Influencing Moderna's Stock This Month

Why Moderna Stock Just Crashed 21%

Cleveland-Cliffs partners with Nucor to potentially bid for US Steel, CNBC reports

Illumina and NVIDIA Just Dropped a Genomics Bombshell

Moderna's Stock Crashes 22%--Pandemic Hero Now Fighting for Survival

Why Madrigal Pharmaceuticals Stock Is Sinking Today

US extends deadline on Nippon's bid for US Steel, offering some hope that the deal is not dead

Steel Wars: U.S. Steel Shares Soar 8% Amid $14.9B Deal Chaos

US Steel Rises on CNBC Report of American Rivals Mulling Bid

Moderna Lowers Full-Year Revenue Outlook, Plans to Cut Cash Costs By $1 Billion

Stock Market Today: Dow Jones Up Even As Nvidia Swoons On Biden Move; This Stock Soars On Bill Ackman Offer (Live Coverage)

Humana, UnitedHealth, CVS Jump On Potential Medicare Advantage Payment Boost

Lululemon Lifts Q4 Sales, Profit Outlook After Holiday Shopping Season

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Why UNH, CVS and HUM Are Advancing Today

Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance

Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition

Performance Overview